To hear about similar clinical trials, please enter your email below
Trial Title:
Mechanism of Gastric Signet Ring Cell Carcinoma Based on Microproteomics
NCT ID:
NCT05985577
Condition:
Gastric Cancer
Signet Ring Cell Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Signet Ring Cell
Conditions: Keywords:
Gastric signet ring cell carcinoma
Molecular Subtypes
Proteomics
Prognostic markers
Drug target
Study type:
Observational [Patient Registry]
Overall status:
Active, not recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Other
Intervention name:
Without any intervention
Description:
There were no special interventions for the two groups.
Arm group label:
Cancer tissues
Arm group label:
Normal adjacent tissues
Summary:
Gastric signet ring cell carcinoma (GSRCC) possesses unique epidemiology and pathogenesis
in the field of cancer, but its incidence is low. Unfortunately, there is currently a
lack of systematic research focusing on the prognostic proteomic features of GSRCC. Given
this knowledge gap, this study aims to comprehensively characterize the proteomic
landscape of GSRCC using a reliable and reproducible DIA-PCT method. This study
objectives include characterizing the heterogeneity of GSRCC, performing molecular
typing, identifying potential biomarkers and therapeutic targets, and providing a
resource for stratified analysis of GSRCC. To achieve these goals, the investigators
selected a cohort of 112 GSRCC patients from a pool of over 10,000 gastric cancer
patients and conducted a proteomic analysis using the DIA-PCT method. This meticulous
approach revealed four novel proteomic subtypes of GSRCC, each exhibiting unique
molecular characteristics. Additionally, the investigators discovered that PRDX2 and
DDX27 can serve as predictive biomarkers for GSRCC, which were further validated in an
independent cohort of 75 GSRCC patients. Furthermore, the investigators paid particular
attention to the MLT-GSRCC subgroup and identified three distinct proteomic clusters
among MLT-GSRCC patients. Subtype 2 within this subgroup demonstrated the poorest
prognosis. Through a rigorous screening process, the investigators determined potential
targets for the treatment of GSRCC. In conclusion, these findings contribute to the
investigators understanding of the heterogeneity of GSRCC and provide valuable resources
for future clinical stratification and targeted treatment strategies.
Criteria for eligibility:
Study pop:
These cases had a signet ring cell content greater than 70% and had not undergone prior
chemotherapy or radiotherapy
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- confirmed GSRCC by pathology, where GSRCC is defined as having a percentage of
signet ring cell ≥ 50%
- patients with complete medical information
- patients with survival follow-up information
Exclusion Criteria:
- patients with other malignant tumors
- presence of other pathological components (e.g., neuroendocrine carcinoma and
squamous cell carcinoma, etc)
- incomplete or lost case information
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Address:
City:
Hangzhou
Zip:
310000
Country:
China
Start date:
March 2, 2023
Completion date:
July 30, 2024
Lead sponsor:
Agency:
Zhejiang Cancer Hospital
Agency class:
Other
Source:
Zhejiang Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05985577
